Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +67.63%
#3 Pons Pons +31.22%
#4 MetaDAO MetaDAO +27.67%
#5 Rain Rain +23.05%
#6 Bedrock Bedrock +21.57%
#7 Ontology Gas Ontology Gas +17.29%
#8 Prom Prom +16.07%
#9 Humanity Humanity +14.61%
#10 Stacks Stacks +13.98%
Coin of the day
QuantixAI QuantixAI
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
CG Oncology Inc. CG Oncology Inc.

CG Oncology Inc.

CGON
Pozycja w akcjach #2843
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops... CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Cena akcji
$78.86
Kapitalizacja rynkowa
$6.96B
Zmiana (1 dzień)
0.80%
Zmiana (1 rok)
210.23%
Kraj
US
Handel CG Oncology Inc. (CGON)

Kategoria

Healthcare
Historia stopy dywidendy dla CG Oncology Inc. (CGON)
Stopa dywidendy (TTM) dla CG Oncology Inc. (symbol akcji: CGON) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla CG Oncology Inc. (CGON) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
Firma Stopa dywidendy Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH